Cover Image

Whole-Genome Sequencing and Molecular Analysis of Ceftazidime-Avibactam-Resistant KPC-Producing <i>Klebsiella pneumoniae</i> from Intestinal Colonization in Elderly Patients

Ceftazidime-avibactam (CAZ-AVI) is an active antibiotic combination of a β-lactam-β-lactamase inhibitor against carbapenemase-producing Enterobacterales. Reports of resistance to CAZ-AVI other than metallo-β-lactamases have increased in recent years. The aim of this study was to analyze KPC-<i>...

Full description

Saved in:

Bibliographic Details
Main Authors:	Giulia Errico (Author), Maria Del Grosso (Author), Michela Pagnotta (Author), Manuela Marra (Author), Maria Carollo (Author), Marina Cerquetti (Author), Elena Fogato (Author), Elisabetta Cesana (Author), Flaminia Gentiloni Silverj (Author), Dorjan Zabzuni (Author), Angelo Rossini (Author), Annalisa Pantosti (Author), Marco Tinelli (Author), Monica Monaco (Author), Maria Giufrè (Author)
Format:	Book
Published:	MDPI AG, 2023-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Detection of KPC-216, a Novel KPC-3 Variant, in a Clinical Isolate of <i>Klebsiella pneumoniae</i> ST101 Co-Resistant to Ceftazidime-Avibactam and Cefiderocol
by: Maria Giufrè, et al.
Published: (2024)

In Vitro Evaluation of Increasing Avibactam Concentrations on Ceftazidime Activity against Ceftazidime/Avibactam-Susceptible and Resistant KPC-Producing <i>Klebsiella pneumoniae</i> Clinical Isolates
by: Marta Palombo, et al.
Published: (2023)

The <i>Klebsiella pneumoniae</i> carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam
by: Sona Garsevanyan, et al.
Published: (2023)

Resistance to Ceftazidime/Avibactam in <i>Klebsiella pneumoniae</i> KPC-Producing Isolates: A Real-Life Observational Study
by: Laura Campogiani, et al.
Published: (2023)

Ceftazidime-Avibactam in Combination with Imipenem as Salvage Therapy for ST11 KPC-33-Producing <i>Klebsiella pneumoniae</i>
by: Li Ding, et al.
Published: (2022)

The Rapid Emergence of Ceftazidime-Avibactam Resistance Mediated by KPC Variants in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> in Zhejiang Province, China
by: Congcong Liu, et al.
Published: (2022)

First Description of Ceftazidime/Avibactam Resistance in a ST13 KPC-70-Producing <i>Klebsiella pneumoniae</i> Strain from Portugal
by: Gabriel Mendes, et al.
Published: (2022)

The Effectiveness of Imipenem-Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase
by: Krisztina M. Papp-Wallace, et al.
Published: (2023)

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing <i>K. pneumoniae</i> Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside
by: Alessandra Oliva, et al.
Published: (2021)

Neonatal Bloodstream Infection with Ceftazidime-Avibactam-Resistant <i>bla</i><sub>KPC-2</sub>-Producing <i>Klebsiella pneumoniae</i> Carrying <i>bla</i><sub>VEB-25</sub>
by: Charalampos Zarras, et al.
Published: (2023)

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i>
by: George L. Daikos, et al.
Published: (2021)

Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against <i>KPC</i>-Producing <i>K. pneumoniae</i> Collected from Bacteremic Patients, 2018 to 2020
by: Federica Bovo, et al.
Published: (2022)

Ceftazidime-avibactam treatment dilemma of bla KPC−2-containing Klebsiella pneumoniae due to the development of co-existence of mixed strains carrying bla KPC−2 or bla KPC−33 in lung transplant recipients
by: Zichen Lei, et al.
Published: (2024)

Synergy between Mecillinam and Ceftazidime/Avibactam or Avibactam against Multi-Drug-Resistant Carbapenemase-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>
by: Karoline Knudsen List, et al.
Published: (2022)

In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant <i>Enterobacterales</i> Isolates from South Korea
by: Taeeun Kim, et al.
Published: (2020)

Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections
by: Quanfeng Liao, et al.
Published: (2022)

Evaluation of Aztreonam and Ceftazidime/Avibactam Synergism against <i>Klebsiella pneumoniae</i> by MALDI-TOF MS
by: Camila Mörschbächer Wilhelm, et al.
Published: (2023)

Analysis of the clinical application of ceftazidime-avibactam in China
by: Qing Wang, et al.
Published: (2022)

Genomic Analysis of Ceftazidime/Avibactam-Resistant GES-Producing Sequence Type 235 <i>Pseudomonas aeruginosa</i> Isolates
by: Raúl Recio, et al.
Published: (2022)

Ceftazidime-Avibactam Treatment for <i>Klebsiella pneumoniae</i> Bacteremia in Preterm Infants in NICU: A Clinical Experience
by: Andrea Marino, et al.
Published: (2023)

Ceftazidime-Avibactam Therapy Versus Ceftazidime-Avibactam-Based Combination Therapy in Patients With Carbapenem-Resistant Gram-Negative Pathogens: A Meta-Analysis
by: Dan Li, et al.
Published: (2021)

Ceftazidime-avibactam induced renal disorders: past and present
by: Yanrong Shi, et al.
Published: (2024)

Effectiveness of Ceftazidime/Avibactam treatment for infections caused by Klebsiella pneumoniae Carbapenemase (KPC), a 30-day mortality perspective. Comparison of results with control groups treated with other antibiotics
by: Patrycja Paschke, et al.
Published: (2024)

Comparison of the inoculum effect of in vitro antibacterial activity of Imipenem/relebactam and Ceftazidime/avibactam against ESBL-, KPC- and AmpC-producing Escherichia coli and Klebsiella pneumoniae
by: Xueting Wang, et al.
Published: (2023)

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resistant Pathogens: A Systematic Review and Network Meta-Analysis
by: Marco Fiore, et al.
Published: (2020)

Synergistic Combination of Aztreonam and Ceftazidime-Avibactam-A Promising Defense Strategy against OXA-48 + NDM <i>Klebsiella pneumoniae</i> in Romania
by: Ioana Miriana Cismaru, et al.
Published: (2024)

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i>
by: Arhodoula Papadomanolaki, et al.
Published: (2022)

Bloodstream Infections Due to Wild-Type <i>Pseudomonas aeruginosa</i>: Carbapenems and Ceftazidime/Avibactam Prescription Rate and Impact on Outcomes
by: Carlo Pallotto, et al.
Published: (2024)

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
by: Alessandro Mancuso, et al.
Published: (2023)

Ceftazidime-Avibactam as a Salvage Treatment for Severely Infected Immunosuppressed Children
by: Zhu L, et al.
Published: (2024)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
by: Goodlet KJ, et al.
Published: (2016)

Use of Ceftazidime-Avibactam in Children Admitted to Pediatric Intensive Care Units
by: André Ricardo Araujo da Silva, et al.
Published: (2024)

High-Level Carbapenem Resistance among OXA-48-Producing <i>Klebsiella</i><i>pneumoniae</i> with Functional OmpK36 Alterations: Maintenance of Ceftazidime/Avibactam Susceptibility
by: Pilar Lumbreras-Iglesias, et al.
Published: (2021)

Antibacterial Activity and Optimal Treatment of Ceftazidime-Avibactam and Aztreonam-Avibactam Against Bloodstream Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae
by: Wei Yu, et al.
Published: (2021)

Efficacy and Safety of Ceftazidime-Avibactam Alone versus Ceftazidime-Avibactam Plus Fosfomycin for the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia: A Multicentric Retrospective Study from the SUSANA Cohort
by: Marco Fois, et al.
Published: (2024)

Experience with ceftazidime-avibactam treatment in a tertiary care center in Saudi Arabia
by: Abdullah Algwizani, et al.
Published: (2018)

Comparative In Vitro Activity of Ceftazidime-Avibactam, Imipenem-Relebactam, and Meropenem-Vaborbactam against Carbapenem-Resistant Clinical Isolates of <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i>
by: Anthony Sophonsri, et al.
Published: (2024)

Meropenem plus Ertapenem and Ceftazidime-Avibactam plus Aztreonam for the Treatment of Ventilator Associated Pneumonia Caused by Pan-Drug Resistant <i>Klebsiella pneumonia</i>
by: Konstantinos Mantzarlis, et al.
Published: (2024)

Off-Label Use of Ceftazidime/Avibactam for the Treatment of Pan-Drug-Resistant <i>Klebsiella pneumoniae</i> in a Neonate: Case Report and Literature Review
by: Iliya Mangarov, et al.
Published: (2023)

Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
by: Maria Di Pietrantonio, et al.
Published: (2022)